Patents by Inventor Maximiliano Vasquez

Maximiliano Vasquez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Highly potent antibodies binding to death receptor 5
    Patent number: 11891446
    Abstract: The present invention is directed toward monoclonal antibodies that bind to death receptor 4 and/or death receptor 5, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: February 6, 2024
    Assignee: GALAXY BIOTECH, LLC
    Inventors: Kyung Jin Kim, Hangil Park, Lihong Wang, Yi Ding, April Zhang, Maximiliano Vasquez
  • RATIONALLY DESIGNED, SYNTHETIC ANTIBODY LIBRARIES AND USES THEREFOR
    Publication number: 20230399386
    Abstract: The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system and are based on rational design informed by examination of publicly available databases of human antibody sequences.
    Type: Application
    Filed: August 30, 2023
    Publication date: December 14, 2023
    Inventors: Maximiliano Vasquez, Michael Feldhaus, Tillman U. Gerngross, Karl Dane Wittrup
  • RATIONALLY DESIGNED, SYNTHETIC ANTIBODY LIBRARIES AND USES THEREFOR
    Publication number: 20230348901
    Abstract: The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system, with or without DH segments derived from other species, and are based on rational design informed by examination of publicly available databases of antibody sequences.
    Type: Application
    Filed: July 1, 2022
    Publication date: November 2, 2023
    Inventors: Maximiliano Vasquez, Michael Feldhaus, Tillman U. Gerngross, K. Dane Wittrup
  • MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2
    Publication number: 20230242650
    Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Application
    Filed: March 10, 2023
    Publication date: August 3, 2023
    Inventors: Kyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez
  • ANTI-CD3-BINDING DOMAINS AND ANTIBODIES COMPRISING THEM, AND METHODS FOR THEIR GENERATION AND USE
    Publication number: 20230151097
    Abstract: Anti-CD3 binding domains and antibodies comprising them, including multispecific antibodies, with, inter alia, desirable T-cell activation and (re)directed target cell killing potency and developability, profiles are provided, as well as methods for their identification, isolation, and generation, and methods for their preparation and use. Reagents for identifying, isolating, selecting, generating and characterizing CD3 binding domains and antibodies comprising them are also provided.
    Type: Application
    Filed: November 11, 2022
    Publication date: May 18, 2023
    Inventors: Laura M. Walker, Robert Pejchal, Eric Krauland, Maximiliano Vasquez, Monica Wai Ling Leung
  • Anti-CD3-binding domains and antibodies comprising them, and methods for their generation and use
    Patent number: 11542330
    Abstract: Anti-CD3 binding domains and antibodies comprising them, including multispecific antibodies, with, inter alia, desirable T-cell activation and (re)directed target cell killing potency and developability, profiles are provided, as well as methods for their identification, isolation, and generation, and methods for their preparation and use. Reagents for identifying, isolating, selecting, generating and characterizing CD3 binding domains and antibodies comprising them are also provided.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: January 3, 2023
    Assignee: Adimab, LLC
    Inventors: Laura M. Walker, Robert Pejchal, Eric Krauland, Maximiliano Vasquez, Monica Wai Ling Leung
  • FC VARIANTS WITH REDUCED EFFECTOR FUNCTION
    Publication number: 20220396622
    Abstract: The present invention provides Fc variants and polypeptides, e.g., antibodies and Fc fusion proteins, comprising such Fc variants. In particular, Fc variants with diminished effector function as a consequence of hinge region and CH2 domain mutations, e.g., LALE-PG, are provided. Such variants maintain antigen-binding and favorable developability profiles and may display improved expressability.
    Type: Application
    Filed: June 24, 2022
    Publication date: December 15, 2022
    Inventors: Robert Pejchal, Eric Krauland, Maximiliano Vasquez, Michael Brown, Anthony Cooper
  • METHOD OF DETECTING TIM-3 USING ANTIBODY MOLECULES TO TIM-3
    Publication number: 20220185883
    Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
    Type: Application
    Filed: September 24, 2021
    Publication date: June 16, 2022
    Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
  • Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R)
    Publication number: 20220153851
    Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.
    Type: Application
    Filed: October 28, 2021
    Publication date: May 19, 2022
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Justin Wong, Maximiliano Vasquez
  • COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3
    Publication number: 20220133889
    Abstract: Combination therapies comprising antibody molecules that specifically bind to TIM-3 are disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.
    Type: Application
    Filed: September 17, 2021
    Publication date: May 5, 2022
    Inventors: Glenn Dranoff, Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
  • Antibodies that bind colony stimulating factor 1 receptor (CSF1R)
    Patent number: 11186646
    Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: November 30, 2021
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Justin Wong, Maximiliano Vasquez
  • Method of detecting TIM-3 using antibody molecules to TIM-3
    Patent number: 11155620
    Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: October 26, 2021
    Assignees: Novartis AG, DANA-FARBER CANCER INSTITUTE, INC., The Children's Medical Center Corporation
    Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
  • HIGHLY POTENT ANTIBODIES BINDING TO DEATH RECEPTOR 4 AND DEATH RECEPTOR 5
    Publication number: 20210238297
    Abstract: The present invention is directed toward monoclonal antibodies that bind to death receptor 4 and/or death receptor 5, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Application
    Filed: February 2, 2021
    Publication date: August 5, 2021
    Applicant: GALAXY BIOTECH, LLC
    Inventors: Kyung Jin Kim, Hangil Park, Lihong Wang, Yi Ding, April Zhang, Maximiliano Vasquez
  • Rationally designed, synthetic antibody libraries and uses therefor
    Patent number: 11008568
    Abstract: The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system, with or without DH segments derived from other species, and are based on rational design informed by examination of publicly available databases of antibody sequences.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: May 18, 2021
    Assignee: Adimab, LLC
    Inventors: Maximiliano Vasquez, Michael Feldhaus, Tillman U. Gerngross, K. Dane Wittrup
  • Rationally designed, synthetic antibody libraries and uses therefor
    Patent number: 11008383
    Abstract: The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system and are based on rational design informed by examination of publicly available databases of human antibody sequences.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: May 18, 2021
    Assignee: Adimab, LLC
    Inventors: Maximiliano Vasquez, Michael Feldhaus, Tillman U. Gerngross, K. Dane Wittrup
  • ANTIBODY LIBRARIES
    Publication number: 20210130813
    Abstract: The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity.
    Type: Application
    Filed: November 2, 2020
    Publication date: May 6, 2021
    Inventors: Maximiliano Vasquez, Arvind Sivasubramanian, Michael Feldhaus
  • Antibody molecules to TIM-3 and uses thereof
    Patent number: 10981990
    Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
    Type: Grant
    Filed: April 6, 2020
    Date of Patent: April 20, 2021
    Assignees: Novartis AG, DANA-FARBER CANCER INSTITUTE, INC., The Children's Medical Center Corporation
    Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
  • FC VARIANTS WITH REDUCED EFFECTOR FUNCTION
    Publication number: 20210087271
    Abstract: The present invention provides Fc variants and polypeptides, e.g., antibodies and Fc fusion proteins, comprising such Fc variants. In particular, Fc variants with diminished effector function as a consequence of hinge region and CH2 domain mutations, e.g., LALE-PG, are provided. Such variants maintain antigen-binding and favorable developability profiles and may display improved expressability.
    Type: Application
    Filed: September 18, 2020
    Publication date: March 25, 2021
    Inventors: Robert Pejchal, Eric Krauland, Maximiliano Vasquez, Michael Brown, Anthony Cooper
  • Highly potent antibodies binding to death receptor 4
    Patent number: 10941204
    Abstract: The present invention is directed toward monoclonal antibodies that bind to death receptor 4 and/or death receptor 5, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: March 9, 2021
    Assignee: GALAXY BIOTECH, LLC
    Inventors: Kyung Jin Kim, Hangil Park, Lihong Wang, Yi Ding, April Zhang, Maximiliano Vasquez
  • METHODS FOR PURIFYING HETERODIMERIC MULTISPECIFIC ANTIBODIES FROM PARENTAL HOMODIMERIC ANTIBODY SPECIES
    Publication number: 20210047387
    Abstract: Methods for purifying multispecific antibodies on interest (MAIs) that co-engage at least two different antigens or epitopes (also referred to targets, used interchangeably throughout), from compositions comprising the MAI and parental homodimeric antibody species are provided, as well as reagents which may be used to practice such methods.
    Type: Application
    Filed: August 21, 2020
    Publication date: February 18, 2021
    Inventors: Juergen Hermann Nett, K. Dane Wittrup, Maximiliano Vasquez